Semaglutide vs AOD-9604
Side-by-side comparison of Semaglutide, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss | AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | GLP-1 Receptor Agonist | hGH C-terminal Fragment |
| Amino acids | 31 | 16 |
| Molecular weight | 4,113.6 Da | 1,815.1 Da |
| Half-life | ~7 days | ~30 min |
| Route(s) | Subcutaneous injection, Oral (Rybelsus) | Subcutaneous, Oral (research) |
| Mechanism & Research | ||
| Primary mechanism | Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… | AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… |
| Research status | FDA Approved | Research Compound |
| Evidence summary | Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… | AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… |
| Protocol & Dosing | ||
| Typical dose | 0.25mg → 2.4mg weekly (weight management) | 300–500 mcg/day |
| Frequency | Once weekly | Once daily |
| Duration | Ongoing (chronic management) | 8–12 weeks |
| Timing | Same day each week, any time | Pre-workout or morning on empty stomach (for metabolic effects) |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Tirzepatide, AOD-9604, Tesamorelin | Semaglutide, Ipamorelin, Tesamorelin |
| Full profile | Read full Semaglutide profile → | Read full AOD-9604 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.